1. Scrip
  2. >>Business

Cipla Warns Of Tough 2H - Pressure On Tender Business, Sanctions-Related Volatility

 
• By Anju Ghangurde

Cipla rang in a “modest” Q2 and management has cautioned that coming quarters might see significant headwinds including the impact of a constrained funding environment on the tender business and US sanctions-related turbulence in some markets.

Storm
COULD CIPLA BE HEADING INTO A TURBULENT SECOND HALF?

After a muted second quarter, Cipla Ltd. has indicated that investors should not expect a dramatic change on the earnings front in the second half, amid what appears to be a challenging business environment in some segments and markets that it operates in.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

 
• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.

Trump’s Tariffs Add To European Warning Of $100bn US Exodus

 
• By Andrew McConaghie

European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.

More from Scrip

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

 
• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.

Trump’s Tariffs Add To European Warning Of $100bn US Exodus

 
• By Andrew McConaghie

European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.